Pharma industry bullish on complex generics and biosimilars
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Subscribe To Our Newsletter & Stay Updated